Drugs / XL019
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00595829 | Dec 2007 → Feb 2009 | acquired polycythemia vera | Exelixis | Terminated | No outcome recorded |
| Phase 1 | NCT00522574 | Aug 2007 → ? | essential thrombocythemia, myelofibrosis, polycythemia | Exelixis | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XL019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00595829 ↗ |
| Action | Inhibit | “selective inhibitor of the cytoplasmic tyrosine kinase JAK2” NCT00522574 ↗ |
| Route | Oral | “XL019 capsules administered orally” NCT00595829 ↗ |
| Target | JAK2 | “selective inhibitor of the cytoplasmic tyrosine kinase JAK2” NCT00522574 ↗ |